Compare BioNTech SE - ADR (BNTX) vs Moderna, Inc. (MRNA) Price & Performance

BioNTech (BNTX) trades at $90.07, down 1.55% today, amid a bearish technical signal and declining revenue trends. The company reported a net loss of $1.14 billion in 2025, with profitability metrics negative, though it maintains a strong cash position of $16.78 billion. Recent news highlights restructuring efforts, including site closures and a $1 billion share buyback, as it pivots focus to oncology pipeline development following reduced COVID-19 vaccine demand.

The outlook remains challenging with persistent losses and competitive pressures, but analyst consensus is bullish with a $129.67 price target. Key risks include execution of the oncology strategy and revenue volatility. The stock's current valuation reflects uncertainty, offering potential upside if pipeline milestones are met, but investors face significant operational and market headwinds.

Moderna (MRNA) trades at $67.01, down 1.85% today, with a bullish technical signal from moving averages. The company continues to post net losses despite beating EPS estimates in recent quarters, with revenue declining from pandemic peaks. Recent news highlights pipeline expansion into oncology and autoimmune diseases, with an FDA decision on its mRNA flu vaccine expected by August 5, 2026.

While Moderna's pipeline diversification offers long-term growth potential, significant risks remain from persistent negative profitability and high valuation multiples. Analyst consensus is cautious with a $49 price target below current levels, suggesting limited near-term upside despite recent positive developments in vaccine approvals and strategic shifts.